Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Bionomics Limited (ASX: BNO, NASDAQ: BNOX) ( Bionomics or Company ), a clinical-stage biopharmaceutical company, is pleased to announce that it has initiated its Phase 2 clinical
United States Prnewswire Bionomics Limited Drug Administration Department Of Psychiatry University Of California San Diego Drs Bionomics Or Company
Source: medindia.net